Home Antibody All anti-BCL2L11 antibodies
Also for BCL2L11 (NM_006538)
| Peptide with sequence C-FNAYYARRLEK, from the C Terminus of the protein sequence according to NP_619528;NP_996886;NP_619529;.|
|Test: Human. Expected from seq similarity: Human
||ELISA: 1:16,000. WB: 0.5-2µg/ml.
|Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.|
| Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.
|Homo sapiens BCL2-like 11 (apoptosis facilitator) (BCL2L11), transcript variant 6|
|BAM; BIM; BOD|
Entrez Gene 10018 Human
|The protein encoded by this gene belongs to the BCL-2 protein family. BCL-2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. The protein encoded by this gene contains a Bcl-2 homology domain 3 (BH3). It has been shown to interact with other members of the BCL-2 protein family, including BCL2, BCL2L1/BCL-X(L), and MCL1, and to act as an apoptotic activator. The expression of this gene can be induced by nerve growth factor (NGF), as well as by the forkhead transcription factor FKHR-L1, which suggests a role of this gene in neuronal and lymphocyte apoptosis. Transgenic studies of the mouse counterpart suggested that this gene functions as an essential initiator of apoptosis in thymocyte-negative selection. Several alternatively spliced transcript variants of this gene have been identified. [provided by RefSeq]. |
|Druggable Genome |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
TA302948 staining (0.5µg/ml) of K562lysate (RIPA buffer, 35µg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence.